KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Net Income (2016 - 2025)

Historic Net Income for Halozyme Therapeutics (HALO) over the last 17 years, with Q3 2025 value amounting to $175.2 million.

  • Halozyme Therapeutics' Net Income rose 2789.12% to $175.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $595.5 million, marking a year-over-year increase of 5172.49%. This contributed to the annual value of $444.1 million for FY2024, which is 5770.61% up from last year.
  • Halozyme Therapeutics' Net Income amounted to $175.2 million in Q3 2025, which was up 2789.12% from $165.1 million recorded in Q2 2025.
  • Halozyme Therapeutics' Net Income's 5-year high stood at $216.6 million during Q3 2021, with a 5-year trough of $22.7 million in Q2 2022.
  • In the last 5 years, Halozyme Therapeutics' Net Income had a median value of $81.8 million in 2023 and averaged $94.2 million.
  • Its Net Income has fluctuated over the past 5 years, first surged by 55707.03% in 2021, then tumbled by 7519.63% in 2022.
  • Quarter analysis of 5 years shows Halozyme Therapeutics' Net Income stood at $66.8 million in 2021, then fell by 13.58% to $57.7 million in 2022, then skyrocketed by 47.98% to $85.4 million in 2023, then skyrocketed by 60.46% to $137.0 million in 2024, then increased by 27.89% to $175.2 million in 2025.
  • Its Net Income stands at $175.2 million for Q3 2025, versus $165.1 million for Q2 2025 and $118.1 million for Q1 2025.